Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of “Buy” from Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received an average recommendation of “Buy” from the sixteen analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $184.8667.

A number of equities research analysts have weighed in on PVLA shares. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $200.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. HC Wainwright upped their price objective on Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, BTIG Research increased their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th.

Palvella Therapeutics Trading Up 1.7%

Shares of PVLA stock opened at $136.70 on Tuesday. Palvella Therapeutics has a 12-month low of $18.23 and a 12-month high of $151.18. The firm’s 50 day moving average is $98.13 and its 200 day moving average is $84.11. The stock has a market capitalization of $1.62 billion, a P/E ratio of -51.98 and a beta of -0.31.

Insider Activity

In other Palvella Therapeutics news, Director Elaine J. Heron acquired 2,400 shares of the stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the purchase, the director directly owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George M. Jenkins bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average price of $125.00 per share, with a total value of $500,000.00. Following the completion of the transaction, the director directly owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently modified their holdings of the business. Group One Trading LLC raised its holdings in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Price T Rowe Associates Inc. MD increased its position in Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after buying an additional 433 shares in the last quarter. Archer Investment Corp purchased a new stake in Palvella Therapeutics in the third quarter worth about $28,000. Bank of America Corp DE raised its stake in shares of Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after buying an additional 515 shares during the period. Finally, Deutsche Bank AG lifted its position in shares of Palvella Therapeutics by 8.7% during the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock valued at $690,000 after buying an additional 528 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.